John Taylor

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH.

Sarnoff Corp. provides contract research services in the fields of electronics, biomedicine and information technology. Its areas of research include optoelectronics, genomics, digital video, lasers and wireless communications. The company was founded in 1942 and is headquartered in Princeton, NJ.

Health Care Services, Inc. provides a range of healthcare services including home medical equipment, home infusion services, home care, and rehabilitation services. The private company is based in Augusta, GA.

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.

Spyryx Biosciences, Inc. develops therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and chronic obstructive pulmonary disease. The company was founded by Robert Tarran in 2013 and is headquartered in Durham, NC.

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Part of Aceragen, Inc., Aceragen, Inc. is a biopharmaceutical company that develops therapeutics for orphan diseases. The company is based in Durham, NC. The company was founded in 2021 by John Clayton Taylor. Aceragen, Inc. (North Carolina) was acquired by Idera Pharmaceuticals, Inc. on September 28, 2022.